AR and breast cancer: There are ongoing trials with metformin47 and a phase II trial of nonsteroidal antiandrogen bicalutamide in women with ER (−)/PR(−)/AR(+) (androgen receptors) BC (ClinicalTrials.gov identifier NCT00468715).